title: Transplanting the elderly: Balancing aging with histocompatibility.
abstract: Across the world, the proportions of senior citizens (i.e. those ≥65years) increase rapidly and are predicted to constitute over 25% of the general population by 2050. In 2012 already 48% of the population with end stage renal disease (ESRD) was aged 65years or older. Transplantation is considered the preferred treatment option for ESRD offering survival advantage over long-term dialysis in the majority of patients. Indeed, acceptable outcomes have been documented for selected patients over the age of 70years or even cases over 80years. The reality of organ scarcity and prolonged waiting times for a deceased donor kidney transplantation, however, indicate that at best 50% of the selected elderly may have realistic expectations to receive a timely transplant offer. By choice or medical selection, access to transplantation also decreases with increasing age. In order to expedite the chance for elderly to receive a kidney transplant dedicated allocation systems have been developed. These allocation systems, like the Eurotransplant Senior Program (ESP), support preferential local allocation of kidneys from older donors to older patients in order to match recipient and graft life while disregarding histocompatibility for HLA antigens. The consequence has been more acute rejection episodes and an increase in immunosuppressive load. In the elderly, the most common cause of graft loss is death with functioning graft and death from infectious diseases is one of the dominant causes. The Eurotransplant Senior DR-compatible Program (ESDP) was designed to further improve the perspective of successful transplantation in the elderly in terms of life and quality of life by re-introducing matching criteria for HLA-DR in the old-for-old algorithm.
authors.affiliation: Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: G J
authors.initials: GJ
authors.lastname: Dreyer
authors.affiliation: Nefrovision/Renine, Dutch Transplant Foundation, Leiden, The Netherlands.
authors.forename: A C
authors.initials: AC
authors.lastname: Hemke
authors.affiliation: Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: M E J
authors.initials: ME
authors.lastname: Reinders
authors.affiliation: Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: jwdefijter@lumc.nl.
authors.forename: J W
authors.initials: JW
authors.lastname: de Fijter
mesh_terms: D000368:Aged; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000276:immunology; D006297:Health Services Accessibility; D006650:Histocompatibility Testing / Q000706:statistics & numerical data*; D006801:Humans; D007166:Immunosuppressive Agents / Q000276:immunology; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000453:epidemiology / Q000601:surgery*; D016030:Kidney Transplantation / Q000401:mortality / Q000706:statistics & numerical data*; D018579:Patient Selection; D011788:Quality of Life; D012042:Registries; D012307:Risk Factors; D009927:Tissue and Organ Procurement; D014850:Waiting Lists
chemical_list: D007166:Immunosuppressive Agents